OneSource profit jumps eightfold to 57.5 crore rupees in second quarter
Key Facts
OneSource Specialty Pharma reported consolidated results for the quarter ended September 30, 2026, the second quarter of its fiscal 2027, with operating revenue of 516.2 crore rupees. Revenue grew 37% year over year and 15% from the previous quarter, according to Moneycontrol, which reported the company's results. Reported net profit rose to about 57.5 crore rupees, eight times its level a year earlier. In trading, the stock rose 7.43% to 1,500 rupees on the Bombay Stock Exchange at 10:15 a.m. local time on October 27, 2026, according to a Business Upturn snapshot. This price reading captures the stock's movement at that point in the session.
Revenue growth was accompanied by stronger expansion in operating profit, with earnings before interest, tax, depreciation and amortization at 163 crore rupees, up 53% from the same period last year and 32% from the previous quarter. The margin on these earnings widened to 31.6%, compared with 28.3% in the second quarter of fiscal 2026. This shows that revenue growth came alongside margin improvement during the period, as well as an increase in operating earnings year over year and quarter over quarter. The company attributed the revenue increase to new capacity for drug-device combinations and strong execution of manufacturing agreements. It also said product launches contributed to growth, without the report specifying the contribution of each factor.
The company launched 12 products during the quarter in North America, the Middle East and North Africa, and Latin America, Moneycontrol reported, citing the company. The launches were among several growth drivers that included new capacity for drug-device combinations and execution of manufacturing agreements, as revenue rose 37% year over year. In business development, the company added two new clients and won six new projects during the period. The wins included two in biologics, while the active request-for-proposal pipeline exceeded 75 opportunities. These figures point to a widening customer base and a growing pipeline of prospective business, alongside product launches that supported activity during the quarter.
The company said its second cartridge line had entered commercial operations, and Chief Executive Officer and Managing Director Neeraj Sharma said, "The second half will see new launches and a significant increase in commercial production volumes." This puts the company's focus for the remainder of fiscal 2027 on new launches and raising commercial production volumes, according to Sharma's remarks cited in the report. The company also reaffirmed its fiscal 2028 targets, setting organic revenue at $400 million and earnings before interest, tax, depreciation and amortization at $160 million. The targets follow a quarter in which revenue was 516.2 crore rupees and operating earnings were 163 crore rupees, with the margin improving year over year. Management's near-term outlook remains tied to product launches and higher commercial production in the second half, while the fiscal 2028 targets set out its stated financial horizon.